This topic merits further investigation because preclinical studies have shown that several cancers expressing high levels of IGF-2 due to IGF-2R mutation and loss of heterozygosity (LOH) are more responsive to both anti-IGF-1R antibodies and anti-sense directed against IGF-2 or IGF-1R [43]–[46]. This evidence concerns the gene IGF2 and cancer.